Alice Stanton

Alice Stanton

Auto-generated profile, based on publicly available information

Alice Stanton

Royal College of Surgeons in Ireland, Dublin, Ireland

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2018 in European Heart Journal
Verified
Journal Article
Closed access
BWBryan Williams
Bryan Williams
GMGiuseppe Mancia
Giuseppe Mancia
WSWilko Spiering
Wilko Spiering
EREnrico Agabiti Rosei
Enrico Agabiti Rosei
MAMichel Azizi
Michel Azizi
SESerap Erdine
Serap Erdine

11 February 2015 in Nature
Verified
Journal Article
Closed access
PDF file
ALAdam E Locke
Adam E Locke
BKBratati Kahali
Bratati Kahali
SBSonja I Berndt
Sonja I Berndt
AJAnne E Justice
Anne E Justice
TPTune H Pers
Tune H Pers
ESElizabeth K. Speliotes
Elizabeth K. Speliotes

5 October 2014 in Nature Genetics
Verified
Journal Article
Open access
PDF file
TCThe Electronic Medical Records and Genomics (eMERGE) Consortium
The Electronic Medical Records and Genomics (eMERGE) Consortium
AWAndrew R Wood
Andrew R Wood
TCThe MIGen Consortium
The MIGen Consortium
TCThe PAGE Consortium
The PAGE Consortium
TSThe LifeLines Cohort Study
The LifeLines Cohort Study
TFTimothy M Frayling
Timothy M Frayling
Timothy Frayling, Joel Hirschhorn, Peter Visscher and colleagues report a meta-analysis of genome-wide association studies for adult height in 253,288 individuals. They identify 697 variants in 423 loci significantly associated with adult height and find that these variants cluster in pathways involved in growth and together explain one-fifth of the heritability for this trait. Using genome-wide data from 253,288 individuals, we identified 697 variants at genome-wide significance that together explained one-fifth of the heritability for adult height. By testing different numbers of variants in independent studies, we show that the most strongly associated ∼2,000, ∼3,700 and ∼9,500 SNPs explained ∼21%, ∼24% and ∼29% of phenotypic variance. Furthermore, all common variants together captured 60% of heritability. The 697 variants clustered in 423 loci were enriched for genes, pathways and tissue types known to be involved in growth and together implicated genes and pathways not highlighted in earlier efforts, such as signaling by fibroblast growth factors, WNT/β-catenin and chondroitin sulfate–related genes. We identified several genes and pathways not previously connected with human skeletal growth, including mTOR, osteoglycin and binding of hyaluronic acid. Our results indicate a genetic architecture for human height that is characterized by a very large but finite number (thousands) of causal variants.

7 March 2006 in Circulation
Verified
Journal Article
Closed access
PDF file
TIThe CAFE Investigators
The CAFE Investigators
CCCAFE Steering Committee and Writing Committee
CAFE Steering Committee and Writing Committee
BWBryan Williams
Bryan Williams
PLPeter S. Lacy
Peter S. Lacy
STSimon M. Thom
Simon M. Thom
WCWriting Committee
Writing Committee
Background— Different blood pressure (BP)–lowering drugs could have different effects on central aortic pressures and thus cardiovascular outcome despite similar effects on brachial BP. The Conduit Artery Function Evaluation (CAFE) study, a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), examined the impact of 2 different BP lowering-regimens (atenolol±thiazide-based versus amlodipine±perindopril-based therapy) on derived central aortic pressures and hemodynamics. Methods and Results— The CAFE study recruited 2199 patients in 5 ASCOT centers. Radial artery applanation tonometry and pulse wave analysis were used to derive central aortic pressures and hemodynamic indexes on repeated visits for up to 4 years. Most patients received combination therapy throughout the study. Despite similar brachial systolic BPs between treatment groups (Δ0.7 mm Hg; 95% CI, −0.4 to 1.7; P =0.2), there were substantial reductions in central aortic pressures with the amlodipine regimen (central aortic systolic BP, Δ4.3 mm Hg; 95% CI, 3.3 to 5.4; P <0.0001; central aortic pulse pressure, Δ3.0 mm Hg; 95% CI, 2.1 to 3.9; P <0.0001). Cox proportional-hazards modeling showed that central pulse pressure was significantly associated with a post hoc–defined composite outcome of total cardiovascular events/procedures and development of renal impairment in the CAFE cohort (unadjusted, P <0.0001; adjusted for baseline variables, P <0.05). Conclusions— BP-lowering drugs can have substantially different effects on central aortic pressures and hemodynamics despite a similar impact on brachial BP. Moreover, central aortic pulse pressure may be a determinant of clinical outcomes, and differences in central aortic pressures may be a potential mechanism to explain the different clinical outcomes between the 2 BP treatment arms in ASCOT.

17 September 2018 in Nature Genetics
Verified
Journal Article
Open access
PDF file
TPThe Million Veteran Program
The Million Veteran Program
EEEvangelos Evangelou
Evangelos Evangelou
HWHelen R. Warren
Helen R. Warren
DMDavid Mosen-Ansorena
David Mosen-Ansorena
BMBorbala Mifsud
Borbala Mifsud
MCMark Caulfield
Mark Caulfield
High blood pressure is a highly heritable and modifiable risk factor for cardiovascular disease. We report the largest genetic association study of blood pressure traits (systolic, diastolic and pulse pressure) to date in over 1 million people of European ancestry. We identify 535 novel blood pressure loci that not only offer new biological insights into blood pressure regulation but also highlight shared genetic architecture between blood pressure and lifestyle exposures. Our findings identify new biological pathways for blood pressure regulation with potential for improved cardiovascular disease prevention in the future.

1 July 2005 in Hypertension
Verified
Journal Article
Closed access
PDF file
EDEamon Dolan
Eamon Dolan
ASAlice Stanton
Alice Stanton
LTLut Thijs
Lut Thijs
KHKareem Hinedi
Kareem Hinedi
NANeil Atkins
Neil Atkins
EOEoin O’brien
Eoin O’brien
The purpose of this study was to determine if ambulatory blood pressure measurement predicted total and cardiovascular mortality over and beyond clinic blood pressure measurement and other cardiovascular risk factors; 5292 untreated hypertensive patients referred to a single blood pressure clinic who had clinic and ambulatory blood pressure measurement at baseline were followed up in a prospective study of mortality outcome. Multiple Cox regression was used to model time to total and cause-specific mortality for ambulatory blood pressure measurement while adjusting for clinic blood pressure measurement and other risk factors at baseline. There were 646 deaths (of which 389 were cardiovascular) during a median follow-up period of 8.4 years. With adjustment for gender, age, risk indices, and clinic blood pressure, higher mean values of ambulatory blood pressure were independent predictors for cardiovascular mortality. The relative hazard ratio for each 10-mm Hg increase in systolic blood pressure was 1.12 (1.06 to 1.18; P <0.001) for daytime and 1.21 (1.15 to 1.27; P <0.001) for nighttime systolic blood pressure. The hazard ratios for each 5-mm Hg increase in diastolic blood pressure were 1.02 (0.99 to 1.07; P =NS) for daytime and 1.09 (1.04 to 1.13; P <0.01) for nighttime diastolic pressures. The hazard ratios for nighttime ambulatory blood pressure remained significant after adjustment for daytime ambulatory blood pressure. These results have 2 important clinical messages: ambulatory measurement of blood pressure is superior to clinic measurement in predicting cardiovascular mortality, and nighttime blood pressure is the most potent predictor of outcome.